Vanbilloen et al., 2000 - Google Patents
Synthesis and biological evaluation of the four isomers of technetium-99m labeled ethylenecysteamine cysteine (99mTc-ECC), the mono-acid derivative of 99mTc-L, L …Vanbilloen et al., 2000
- Document ID
- 12169360326160555521
- Author
- Vanbilloen H
- Cleynhens B
- Verbruggen A
- Publication year
- Publication venue
- Nuclear medicine and biology
External Links
Snippet
A few years ago 99mTc-ethylenedicysteine (99mTc-L, L-EC) had been proposed as an interesting substitute for technetium-99m labeled mercaptoacetyltriglycine (MAG3) as renal function tracer agent. It possesses in its structure two carboxylate functions and is in this …
- GKLVYJBZJHMRIY-OUBTZVSYSA-N technetium-99 data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 [99Tc] 0 title abstract description 20
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0497—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Verbruggen et al. | Technetium-99m-L, L-ethylenedicysteine: a renal imaging agent. I. Labeling and evaluation in animals | |
| Inoue et al. | Biodistribution studies on L-3-(fluorine-18)(fluoro-alpha-methyl) tyrosine: A potential tumor-detecting agent | |
| Eckelman | Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems | |
| Eshima et al. | 99mTc renal tubular function agents: current status | |
| Volkert et al. | Technetium-99m chelates as radiopharmaceuticals | |
| Qu et al. | Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm | |
| Welling et al. | Infection detection in mice using 99mTc-labeled HYNIC and N2S2 chelate conjugated to the antimicrobial peptide UBI 29-41 | |
| Yang et al. | Formulation of 68Ga BAPEN kit for myocardial positron emission tomography imaging and biodistribution study | |
| Choi et al. | An improved kit formulation of a dopamine transporter imaging agent:[Tc-99m] TRODAT-1 | |
| Vanbilloen et al. | Synthesis and biological evaluation of the four isomers of technetium-99m labeled ethylenecysteamine cysteine (99mTc-ECC), the mono-acid derivative of 99mTc-L, L-ethylenedicysteine | |
| Cutler et al. | Labeling and in vivo evaluation of novel copper (II) dioxotetraazamacrocyclic complexes | |
| Taylor et al. | Comparison of technetium-99m-LL-EC isomers in rats and humans | |
| Saha | Characteristics of specific radiopharmaceuticals | |
| Sun et al. | In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands | |
| Lipowska et al. | Monoanionic 99mTc-tricarbonyl-aminopolycarboxylate complexes with uncharged pendant groups: radiosynthesis and evaluation as potential renal tubular tracers | |
| Mahmood et al. | 10. TECHNETIUM RADIOPHARMACEUTICALS | |
| Vanbilloen et al. | Importance of the two ester functions for the brain retention of 99mTc-labelled ethylene dicysteine diethyl ester (99mTc-ECD) | |
| Liu et al. | Nitriles form mixed-coligand complexes with 99mTc-HYNIC-peptide | |
| Vanbilloen et al. | Complexes of technetium-99m with tetrapeptides containing one alanyl and three glycyl moieties | |
| Rennen et al. | PET imaging of infection with a HYNIC-conjugated LTB4 antagonist labeled with F-18 via hydrazone formation | |
| Kieffer et al. | Synthesis and biological evaluation of a technetium-99m (I)-tricarbonyl-labelled phenyltropane derivative | |
| Vanbilloen et al. | Development and biological evaluation of 99mTc-BAT-tropane esters | |
| Ferro-Flores et al. | Labeling of biotin with [166Dy] Dy/166Ho as a stable in vivo generator system | |
| Vanbilloen et al. | RP-HPLC separation of the diastereomers of technetium-99m labelled tropanes and identity confirmation using radio-LC-MS | |
| Prinsen et al. | Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis |